TY - JOUR
T1 - A pathologic link between Wilms tumor suppressor gene, WT1, and IFI16
AU - Kim, Marianne K.H.
AU - Mason, Jacqueline M.
AU - Li, Chi Ming
AU - Berkofsky-Fessler, Windy
AU - Jiang, Le
AU - Choubey, Divaker
AU - Grundy, Paul E.
AU - Tycko, Benjamin
AU - Licht, Jonathan D.
N1 - Funding Information:
Abbreviations: GST, glutathione-S-Transferase; IFI16, interferon-inducible protein 16; shRNA, short hairpin RNA; siRNA, small interfering RNA; STAT3, signal transducer and activators of transcription protein 3; WT1, Wilms tumor gene Address all correspondence to: Jonathan D. Licht, MD, Division of Hematology/ Oncology, Northwestern University, Feinberg School of Medicine, Lurie 5-123, 303 E. Superior Street, Chicago, IL 60611. E-mail: [email protected] 1Supported by NIH grant R01CA102270 to B. T. and J. D. L. and by a Postdoctoral Fellowship (#PF-05-252-01-MGO) from the American Cancer Society to M. K.-H. K. 2This article refers to supplementary materials, which are designated by Figures W1, W2, W3, and W4 and are available online at www.neoplasia.com. Received 19 September 2007; Revised 7 November 2007; Accepted 8 November 2007 Copyright © 2008 Neoplasia Press, Inc. All rights reserved 1522-8002/08/$25.00 DOI 10.1593/neo.07869
PY - 2008/1
Y1 - 2008/1
N2 - The Wilms tumor gene (WT1) is mutated or deleted in patients with heredofamilial syndromes associated with the development of Wilms tumors, but is infrequently mutated in sporadic Wilms tumors. By comparing the microarray profiles of syndromic versus sporadic Wilms tumors and WT1-inducible Saos-2 osteosarcoma cells, we identified interferon-inducible protein 16 (IFI16), a transcriptional modulator, as a differentially expressed gene and a candidate WT1 target gene. WT1 induction in Saos-2 osteosarcoma cells led to strong induction of IFI16 expression and its promoter activity was responsive to the WT1 protein. Immunohistochemical analysis showed that IFI16 and WT1 colocalized in WT1-replete Wilms tumors, but not in normal human midgestation fetal kidneys, suggesting that the ability of WT1 to regulate IFI16 in tumors represented an aberrant pathologic relationship. In addition, endogenous IFI16 and WT1 interacted in vivo in two Wilms tumor cell lines. Furthermore, IFI16 augmented the transcriptional activity of WT1 on both synthetic and physiological promoters. Strikingly, short hairpin RNA (shRNA)-mediated knockdown of either IFI16 or WT1 led to decreased growth of Wilms tumor cells. These data suggest that IFI16 and WT1, in certain cellular context including sporadic Wilms tumors, may support cell survival.
AB - The Wilms tumor gene (WT1) is mutated or deleted in patients with heredofamilial syndromes associated with the development of Wilms tumors, but is infrequently mutated in sporadic Wilms tumors. By comparing the microarray profiles of syndromic versus sporadic Wilms tumors and WT1-inducible Saos-2 osteosarcoma cells, we identified interferon-inducible protein 16 (IFI16), a transcriptional modulator, as a differentially expressed gene and a candidate WT1 target gene. WT1 induction in Saos-2 osteosarcoma cells led to strong induction of IFI16 expression and its promoter activity was responsive to the WT1 protein. Immunohistochemical analysis showed that IFI16 and WT1 colocalized in WT1-replete Wilms tumors, but not in normal human midgestation fetal kidneys, suggesting that the ability of WT1 to regulate IFI16 in tumors represented an aberrant pathologic relationship. In addition, endogenous IFI16 and WT1 interacted in vivo in two Wilms tumor cell lines. Furthermore, IFI16 augmented the transcriptional activity of WT1 on both synthetic and physiological promoters. Strikingly, short hairpin RNA (shRNA)-mediated knockdown of either IFI16 or WT1 led to decreased growth of Wilms tumor cells. These data suggest that IFI16 and WT1, in certain cellular context including sporadic Wilms tumors, may support cell survival.
UR - http://www.scopus.com/inward/record.url?scp=38649105182&partnerID=8YFLogxK
U2 - 10.1593/neo.07869
DO - 10.1593/neo.07869
M3 - Article
C2 - 18231640
AN - SCOPUS:38649105182
SN - 1522-8002
VL - 10
SP - 69
EP - 78
JO - Neoplasia
JF - Neoplasia
IS - 1
ER -